Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7861-7865

  Gajewski, Thomas F ^a   Sosman, Jeffrey ^b   Gerson, Stanton L ^c   Liu, Lili ^c   Dolan, Eileen ^a   Lin, Shang ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; 6 O BENZYLGUANINE; CARBON MONOXIDE; CARMUSTINE;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DNA DAMAGE; DRUG MECHANISM; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LIVER DYSFUNCTION; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBON MONOXIDE; CARMUSTINE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GUANINE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 27744480123     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0060     Document Type: Article

References (26)

1. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
2. Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997;3:837-47.
3. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
4. Moriwaki S, Nishigori C, Takebe H, Imamura S. O6-alkylguanine-DNA alkyltransferase activity in human malignant melanoma. J Dermatol Sci 1992;4:6-10.
5. Magull-Seltenreich A, Zeller WJ. Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase. J Cancer Res Clin Oncol 1995;121:225-9.
6. Bobola MS, Berger MS, Silber JR. Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol Carcinog 1995;13:81-8.
7. Wedge SR, Newlands ES. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 1996;73:1049-52.
8. Dolan ME, Pegg AE, Biser ND, Moschel RC, English HF. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol 1993;32:221-5.
9. Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol 1993;45:483-91.
10. Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1993;32:471-6.
11. Dolan ME, Chae MY, Pegg AE, Mullen JH, Friedman HS, Moschel RC. Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res 1994;54:5123-30.
12. Spiro TP, Gerson SL, Liu L, et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999;59:2402-10.
13. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000;6:3025-31.
14. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 1998;16:1803-10.
15. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.
16. Stefan TL, Ingalls ST, Gerson SL, Willson JK, Hoppel CL. Determination of O6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;681:331-8.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
18. Dolan ME, Posner M, Karrison T, et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res 2002;8:2519-23.
19. Chen J, Zhang Y, Sui J, Chen Y. O6-methylguanine-DNA methyltransferase activity and sensitivity of human tumor cell lines to bis- chloroethylnitrosourea. Chin Med Sci J 1992;7:187-90.
20. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
21. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther 2002;5:381-7.
22. Kaina B, Muhlhausen U, Piee-Staffa A, et al. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with non-conjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther 2004;311:585-93.
23. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
24. Lee SM, Thatcher N, Crowther D, Margison GP. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69:452-6.
25. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001;7:2309-17.
26. Long L, Moschel RC, Dolan ME. Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism. Biochem Pharmacol 2001;61:721-6.